Introduction and Objective: To evaluate the impact of AID systems over time and DKA at diagnosis of T1D on HbA1c values in the first two years after diagnosis. Methods: This multicentre cohort study recruited individuals 18 years, diagnosed with T1D between 2020 and 2021 and followed for two years in 33 Italian pediatric diabetes centres. HbA1c was evaluated at diagnosis, at one and two years after diagnosis. For each time point the use of AID was assessed. HbA1c values over time were evaluated according to AID use by mixed-effects regression models adjusted for clinical characteristics at diagnosis. Results: Overall, 1164 cases were included. AIDs were initiated within 60 days from diagnosis in 238 individuals, between 61 days and 1 year in 165, and between 1 and 2 years in 157; 604 never used AIDs. DKA at diagnosis occurred in more than 55% of participants. Higher HbA1c was associated with DKA at diagnosis, and lower HbA1c with AID use (Table 1). Conclusion: The study demonstrates that DKA continues to affect HbA1c two years after the diagnosis, regardless of the use of AID systems over time. These findings highlight the need for continued efforts to prevent DKA at diagnosis of T1D. Disclosure V. Tiberi: None. V. Cherubini: Speaker's Bureau; Ended; Sanofi. Research Support; Current; Lilly, Novo Nordisk, Abbott. Research Support; Ended; Medtronic. A. Faragalli: None. R. Gesuita: None.
Tiberi et al. (Fri,) studied this question.